Cyclopharm Limited (ASX:CYC)
| Market Cap | 57.84M -18.7% |
| Revenue (ttm) | 34.42M +12.1% |
| Net Income | -18.32M |
| EPS | -0.16 |
| Shares Out | 125.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 245,908 |
| Open | 0.4250 |
| Previous Close | 0.4250 |
| Day's Range | 0.4250 - 0.4600 |
| 52-Week Range | 0.3300 - 1.2900 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Cyclopharm
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 ... [Read more]
Financial Performance
In 2025, Cyclopharm's revenue was 32.33 million, an increase of 17.24% compared to the previous year's 27.57 million. Losses were -17.22 million, 30.5% more than in 2024.
Financial StatementsNews
Cyclopharm Earnings Call Transcript: Q3 2026
Q3 U.S. revenue hit a record $1.62 million, up 124% YoY, as existing-site consumables supplied 76% of U.S. sales. New guidelines accelerated pipeline activity, while monthly cash burn declined to AUD 0.9 million in Q3.
Cyclopharm Slides: Q3 2026
Cyclopharm has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Half Year 2026 Cyclopharm Ltd Earnings Presentation Transcript
Half Year 2026 Cyclopharm Ltd Earnings Presentation Transcript
Cyclopharm Earnings Call Transcript: H1 2026
Record half-year revenue up 14% to AUD 17.5 million, driven by 74% U.S. growth and margin expansion. New international guidelines name Technegas as preferred agent, supporting accelerated U.S. adoption and expansion into broader indications.
Cyclopharm Earnings release: H1 2026
Cyclopharm released its H1 2026 earnings on September 1, 2026, summarizing the period's financial results.
Cyclopharm Quarterly report: H1 2026
Cyclopharm has published its H1 2026 quarterly earnings report on September 1, 2026.
Cyclopharm Slides: H1 2026
Cyclopharm has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 1, 2026.
Cyclopharm Slides: Corporate presentation
Cyclopharm has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
Cyclopharm Slides: FY 2026
Cyclopharm has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 7, 2026.
Cyclopharm Annual report: H2 2025
Cyclopharm has published its H2 2025 annual report on February 2, 2026.
Cyclopharm Earnings release: H2 2025
Cyclopharm released its H2 2025 earnings on February 2, 2026, summarizing the period's financial results.